.png){kind=small}
.png){kind=small}
BackTable / ENT / Contributor
Dr. Adam Luginbuhl
Otolaryngologist
Dr. Adam Luginbuhl is an Associate Professor of Otolaryngology Head and Neck Surgery at Thomas Jefferson University.
Listen to Dr. Adam Luginbuhl on the BackTable Podcast
The BackTable Podcast is a knowledge resource by physicians for physicians. Learn from the experiences and expertise of Dr. Adam Luginbuhl and get practical advice on how to build your practice by listening to the BackTable Podcast.
Stay Up To Date
Follow:
Subscribe:
Sign Up:
About Dr. Adam Luginbuhl
Dr. Luginbuhl is at the cutting edge of research bridging the gap of new immunotheraputic options, radioactive isotopes and surgery to offer a broad array of clinical trials and treatment options for head and neck cancer. His recent work with CDDO compounds in the laboratory have resulted in preventing some of the profound side effects experienced in radiation therapy.
Additionally he is deeply involved in Haitian mission work, taking 3-4 trips/year. He and his partners have performed the first free tissue transfer and continue to operate regularly in 2 different hospitals. He is leading a coalition to bring oncologic care to Haiti through radiation and chemotherapy.
Learn more by visiting Dr. Adam Luginbuhl's practice:
Podcasts Featuring Dr. Adam Luginbuhl
.png){kind=small}
ENT Episode #247
When treating head and neck cancer, how can you tell the difference between true disease progression and pseudoprogression? In this episode of the BackTable Podcast, we discuss the practical implementation of the KEYNOTE-689 trial published in the New England Journal of Medicine, which demonstrated the benefit of adding neoadjuvant and adjuvant immunotherapy to standard head and neck cancer care. Our tumor board panel includes Dr. Mihir Patel, a head and neck surgeon from UNC Chapel Hill, Dr. Siddharth Sheth, a head and neck medical oncologist from UNC, Dr. Jennifer Johnson, a professor of medical oncology and otolaryngology at Sidney Kimmel Comprehensive Cancer Center, and Dr. Adam Luginbuhl, a head and neck surgical oncologist at Thomas Jefferson University.
.png){kind=small}
Tumor Board Episode #33
When treating head and neck cancer, how can you tell the difference between true disease progression and pseudoprogression? In this episode of the BackTable Podcast, we discuss the practical implementation of the KEYNOTE-689 trial published in the New England Journal of Medicine, which demonstrated the benefit of adding neoadjuvant and adjuvant immunotherapy to standard head and neck cancer care. Our tumor board panel includes Dr. Mihir Patel, a head and neck surgeon from UNC Chapel Hill, Dr. Siddharth Sheth, a head and neck medical oncologist from UNC, Dr. Jennifer Johnson, a professor of medical oncology and otolaryngology at Sidney Kimmel Comprehensive Cancer Center, and Dr. Adam Luginbuhl, a head and neck surgical oncologist at Thomas Jefferson University.
Tumor Board Episode #32
While the standard for adjuvant head and neck cancer treatment hasn't changed since 2004, a new trial using perioperative pembrolizumab is forcing clinicians to rethink their entire workflow, starting with diagnosis. In this episode of the BackTable Podcast, head and neck surgical oncologist Dr. Adam Luginbuhl is joined by colleagues Dr. Dylan Roden and Dr. Ravindra Uppaluri to discuss the implementation and implications of the Keynote-689 trial, which introduced neoadjuvant and adjuvant immunotherapy for locally advanced head and neck cancer.
ENT Episode #245
While the standard for adjuvant head and neck cancer treatment hasn't changed since 2004, a new trial using perioperative pembrolizumab is forcing clinicians to rethink their entire workflow, starting with diagnosis. In this episode of the BackTable Podcast, head and neck surgical oncologist Dr. Adam Luginbuhl is joined by colleagues Dr. Dylan Roden and Dr. Ravindra Uppaluri to discuss the implementation and implications of the Keynote-689 trial, which introduced neoadjuvant and adjuvant immunotherapy for locally advanced head and neck cancer.
Get in touch!
We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Podcasts
Topics
More Contributors
Dr. Ashley Agan
Dr. Aparna Baheti
Dr. Peter Bream
Dr. Daniel Chelius
Dr. Andrew Day
Dr. Ariel Frost